Table 1 - uploaded by Marcilio Cunha Filho
Content may be subject to copyright.
Download
View publication
Comparison of Drug Substances in Simple Topical Antifungal Products Registered in Brazil and in the United States.

Comparison of Drug Substances in Simple Topical Antifungal Products Registered in Brazil and in the United States.

Source publication
Table 1 . Comparison of Drug Substances in Simple Topical Antifungal...
Table 2 . Comparison of Drug Substances in Combined Topical Antifungal...
Table 3 . Clinical Profiles of Superficial Mycoses From Brazil and...
Table 4 . Dosage Forms Registered for Topical Antifungal Products in...
Regulatory Requirements and Innovation: A Comparison of the Dermatologic Antifungal Drug Product Markets in Brazil and United States
Article
Full-text available
  • Oct 2018
Background: Development of novel dermatological topical products for the treatment of cutaneous fungal infections is a constant necessity, especially in developing countries. Through public health policies, many developing countries have facilitated in the last decades the entry of generic products, which can be superficially seen as a threat to i...
Cite
Download full-text

Context in source publication

Context 1
... total of 664 topical antimycotics drug products were regis- tered in Brazil, and 106 were registered in the US. The main isolated drug registered in Brazil was ketoconazole (22.3%), while the most common isolated drug in the US was ciclopirox (27.4%) (Table 1). ...